1 Arthritis Foundation (2013). Spotting Arthritis in Spot. Retrieved 09 2013, 02, from Arthritis Foundation.

2 Global Animal (2012). Stiff Joints? How To Treat Dog Arthritis . Retrieved February 18, 2013, from Global Animal.

3 Richardson DC, Schroenherr WD, Zicker SC (1997). Nutritional management of osteoarthritis. Vet Clin North Am, Small Anim Pract. 27: 883-911.

4 Elliot D (2007). Nutritional management of canine arthritis. Vet Focus 17: 43-48.

5 ASPCA (2013). Hip Dysplasia. Retrieved 9 13, 2013, from ASPCA.

6 Muir HCS (1987). Pathological and biochemical changes in cartilage and other tissues of the canine knee resulting from induced joint instability. In: Joint Loading: Biology and Health of Articular Structures. Bristol. pp. 47-63.

7 Vaughan-Scott T, Taylor JH (1997). The pathophysiology and medical management of canine osteoarthritis. J S Afr Vet Assoc. 68: 21-25.

8 Bellamy N, Carr A, Dougados M, Shea B, Wells G (2001). Towards a definition of "differences" in osteoarthritis. J Rheumatol. 28: 427-430.

9 Lennon E, Marcellin-Little D (2005). Canine Osteoarthritis. Retrieved August 5, 2013 from Arthritis M.D.

10 Renberg WC (2005). Pathophysiology and management of arthritis. Vet Clin Small Anim. 35: 1073-1091.

11 Burns K (2006). Research targets and conditions of older cats and dogs. J Am Vet Med Assoc. 229: 482-483.

12 Centers for Disease Control and Prevention (CDC) Arthritis-Basic-Definition-Osteoarthritis. Retrieved June 18, 2010.

13 Dore D, Martens A, Quinn S, Ding C, Winzenberg C, et al.(2010). Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospecitve study in older adults. Arthr Res Ther. 12: R222.

14 Umlauf D, Frank S, Pap T, Bertrand J (2010). Cartilage, biology, pathology, and repair. Cell Mol Life Sci. 67: 4197-4211.

15 Loeser RF (2013) Osteoarthritis year in review 2013: biology. Osteoarthr Cartil. 21: 1436-1442.

16 Reid DM, Miller GC (2008). Clinical Trails in Rheumatoid Arthritis and Osteoarthritis.Aberdeen, UK: Springer-Verlag London Limited.

17 Thote T, Lin ASP, Raji Y, Moran S, Stevens HY, et al. (2013). Localized 3D analysis of cartilage composition and morphology in small animal models of joint degeneration. Osteoarthr Cartil. 21: 1132-1141.

18 Lafeber FPJG, van Spil WE (2013). Osteoarthritis year 2013 in review: biomarkers; reflecting before moving forward, one step at a time. Osteoarthr Cartil. 21: 1452-1464.

19 Deparle LA, Gupta RC, Canerdy TD, Goad JT, D'Altilio M, et al. (2005). Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. J Vet Pharmacol Ther. 28: 385-390.

20 D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, et al. (2007). Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mechan Methods.17:189-196.

21 Peal A, D'Altilio M, Simms C, Alvey M, Gupta RC, et al. (2007). Therapeutic efficacy and safety of undenatured type-II collagen (UC-II) alone or in combination with (-) hydroxycitric acid and chromemate in arthritic dogs. J Vet Pharmacol Ther. 30: 275-278.

22 Gupta RC, Canerdy TD, Lindley J, Konemman M, Minniear J, et al. (2012). Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutri. 96: 770-777.

23 Lawley S, Gupta RC, Goad JT, Canerdy TD, Kalidindi SR (2013). Anti-inflammatory and anti-arthritic efficacy and safety of purified Shilajit in moderately arthritic dogs. J Vet Sci Anim Husband. 1: 302.

24 Fahie MA, Ortolano GA, Guercio V, Schaffer JA, et al. (2013). A randomized controlled trial of the efficacy of autologous platelet therapy for the treatment of osteoarthritis. J Am Vet Med Assoc. 243:1291-1297.

25 Osteoarthritis in Dogs-Signs and Symptoms of Arthritis and Osteoarthritis. (2012). Retrieved August 8, 2013, from Osteoarthritis in Dogs.

26 Calvo E, Palacios I, Delgado E, Ruiz-Cabello L, et al. (2001). High-resolution MRI detects cartilage swelling at the early stages of experimental osteoarthritis. Osteoarthr Cartil. 9: 463-472.

27 Kumar D, Wyatt CR, Lee S, Nardo L, Link TM, et al. (2013). Association of cartilage defects, and other MRI findings with pain and function in individuals with mild-moderate radiographic hip osteoarthritis and controls. Osteoarthr Cartil. 21: 1685-1692.

28 McCoy AM, Toth F, Dolvik NI, Ekman S, Ellermann J, et al. (2013). Articular osteochondrosis: a comparison of naturally-occurring human and animal disease. Oateoarthr Cartil. 21: 1638-1647.

29 Mosher TJ, Walker EA, Petscavage-Thomas J, Guermazi A (2013). Osteoarthritis year 2013 in review: Imaging. Osteoarthr Cartil. 21: 1425-1435.

30 Piscaer TM, Waarsing JH, Kops N, Pavljasevic P, et al. (2008). In vivo imaging of cartilage degeneration using microCT-arthrography. Oateoarthr Cartil. 16: 1011-1017.

31 Abadie E, Ethgen D, Avouac B, Bouvenot G, Branco J, et al. (2004). Recommendations for the use of new methods to assess the efficacy of disease –modifying drugs in the treatment of osteoarthritis. Osteoarthr Cartil. 12: 263-268.

32 Moreau M, Dupuis J, Bonneau NH, Desnoyers M (2003). Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 152: 323-329.

33 Neil KM, Caron JP, Orth MW (2005). The role of glucosamine and chondroitin sulfate in treatment and prevention of osteoarthritis in animals. J Am Vet Med Assoc. 226:1079-1088.

34 McCarthy G, O'Donovan J, Jones B, et al. (2007). Randomized double-blind, positive –controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 174: 54-61.

35 Sawaya S (2007). Physical and altenative therapies in the management of arthritic patients. IVIS Vet Focus 17: 37-42.

36 Bergh MS, Budsberg SC. (2005). The coxib NSAIDs : potential clinical and pharmacologic importance in veterinary medicine. J Vet Int Med. 19: 633-643.

37 Monteiro-Steagall BP, Steagall PV, Lascelles BD (2013). Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Int Med. 27: 1011- 1019.

38 Sessions JK, Reynolds LR, Budsberg SC (2005). In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res. 66: 812-827.

39 Raekillio M, Hielm-Bjorkman A, Kejonen J, Salonen H, Sankari SM (2006). Evaluation of adverse effects of long-term orally administered carprofen in dogs. J Am Vet Med Assoc. 228: 876-880.

40 Canine Arthritis (2006). Retrieved 07 2013, from Canine Arthritis.

41 Innes JF, Clayton J, Lascelles B (2010). Review of the safety and efficacy of long- term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 166 (8): 226-230.

42 Rychel J (2010). Diagnosis and Treatment of Osteoarthritis. Topics Compan Anim Med. 25: 20-25.

43 Goggs R, Vaughan-Thomas A, Clegg PD, Carter SD, Innes, JF, et al. (2005). Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutri. 45: 145-164.

44 Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010). Effect of glucosamine or chondroitin on the osteoarthritis progression: a meta-analysis. Rheumatol Int. 30: 357-363.

45 Canine Osteoarthritis Management with Glucosamine for Dogs (2012). Retrieved 8 19, 2013.

46 Ohnishi A, Osaki T, Matahira Y, Tsuka T, Imagawa T, et al. (2013). Correlation of plasma amino acid concentrations and chondroprotective effects of glucosamine and fish collagen peptide on the development of osteoarthritis. J Vet Med Sci. 75: 497-502.

47 Iovu M, Dumais G, Du Souich P (2008). Anti-inflammatory activity of chondroitin sulfate. Osteoarthr Cartil 16: S14-18.

48 Biswas TK, Polley G, Pandit S, Pratip DK, et al. (2010). Effects of adjunct therapy of a proprietary herbo-chromium supplement in type 2 diabetes: a randomized clinical trial. Intl J Diabetes Devel Countr 30: 153-161.

49 Hua Y, Clark S, Ren J, Sreejayan N (2012). Molecular mechanisms of chromium in alleviating insulin resistance. J Nutri Biochem. 23: 313-319.

50 Ryan GJ, Wanko NS, Redman AR, Cook CB (2003). Chromium as adjunctive treatment for type 2 diabetes. Ann Pharmacother 37: 876-885.

51 Rains JL, Jain SK (2011). Oxidative stress, insulin signaling, and diabetes. Free Rad Biol Med. 50: 567-575.

52 Acharya SB, Frotan MH, Goel RK, Tripathy SK, Das PK (1988). Pharmacological actions of Shilajit. Indian J Exp Biol. 26: 775-777.

53 Goel RK, Banerjee RS, Acharya SB (1990). Antiulcerogenic and antiinflammatory studies with shilajit. J Ethnopharmacol. 29: 95-103.

54 Bhattacharya SK, Sen AP, Ghosal S (1995). Effects of Shilajit on biogenic free radicals. Phytother Res 9: 56-59.

55 Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, Bigi V (1997). Systemic administration of defined extracts from Withania somnifera (Indian Ginseng) and Shilajit differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. Neurochem Intl. 30: 181-190.

56 Park JS, Kim GY, Han K (2006). The spermatogenic and ovogenic effects of chronically administered Shilajit to rats. J Ethnopharmacol. 107: 349-353.

57 Agarwal SP, Khanna R, Karmarker R, Anwar K, Khar RK (2007). Shilajit: a review. Phytother Res. 21(5):401-405.

58 Tripathi YB, Shukla S, Chaurasia S, Chaturvedi S (1996). Antilipid peroxidative property of Shilajit. Phytother Res. 10: 269-270.